TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06519266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHP
Description: Patients will be treated with 2 cycles of PHP (CHEMOSAT® Hepatic Delivery System for Melphalan) six weeks apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI1/NIVO3
Description: Patients will be treated with 2 cycles of i.v. ipilimumab 1mg/kg and nivolumab 3mg/kg q3w, followed by continued i.v. nivolumab 480mg q4w up to 1 year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPI3/NIVO1
Description: Patients will be treated with 4 cycles of intravenous (i.v.) infusion with ipilimumab 3mg/kg and nivolumab 1mg/kg q3w followed by continued i.v. nivolumab 480mg q4w up to 1 year.
Study: NCT04452097

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells + best supportive care
Description: hUC-MSC product will be administered intravenously in addition to the standard of care treatment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells + best supportive care
Description: hUC-MSC product will be administered intravenously in addition to the standard of care treatment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells + best supportive care
Description: hUC-MSC product will be administered intravenously in addition to the standard of care treatment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells + best supportive care
Description: hUC-MSC product will be administered intravenously in addition to the standard of care treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control + best supportive care
Description: Placebo control will be administered intravenously in addition to the standard of care treatment.
Study: NCT06253585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm Alarm- Crystalloids
Description: The study uses an algorithm implemented within the Electronic Health Record (EHR). This algorithm identifies patients who belong to a sepsis subphenotype known as Group D, in whom published data has shown a mortality benefit from balanced crystalloids compared to normal saline.~The intervention is an EHR alert when clinicians order normal saline on Group D patients randomized to intervention. In the intervention arm, if a clinician orders normal saline in a patient classified as Group D, there will be an EHR alert to change the order to balanced crystalloids (i.e., Lactated Ringer or Plasma-Lyte solution).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Enrolled patients who are classified to Group D by the algorithm will be randomized within the electronic health record to usual care. In the usual care arm, the clinicians will not have any feedback from the algorithm and will not know the Group classification of their patient or the recommended fluid type.
Study: NCT06290622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab, INCAGN02385, INCAGN02390
Description: Treatment:~Retifanlimab -infused over 60 minutes for C1D1 followed by a 60-minute observation period. If no infusion related reactions are observed infusion may be reduced to 30 minutes and no further observation period is needed for future cycles. If there is a reaction continue with 60 minute infusion and observation period for following cycle. Retifanlimab should always be administered first.~INCAGN02385 and INCAGN02390 -individually administered over 30 minutes one after another. For first infusions of retifanlimab, INCAGN02385 and INCAGN02390, a 4 hour observation period is necessary after completion of all infusion. If no infusion related reactions are observed, for subsequent infusions no further observation period is needed for future cycles.
Study: NCT05237687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Patients will be randomly assigned to sirolimus or standard of care
Study: NCT05573555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-471
Description: Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Daily oral dosages of ribociclib consecutively for 21 days followed by 7 days off treatment, cycles lasting 28 days
Study: NCT05529992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velaglucerase Alfa
Description: VPRIV intravenous infusion every other week for 60 minutes.
Study: NCT05645562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education program
Description: 1. Types of pain (peripherical and central pain)~2. Pain as information.~3. Benign and harmful pain~4. Psychological factors and pain in sport (Injuries, catastrophizing and pain)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-care education program
Description: 1. The importance of resting~2. Nutritional habits~3. Recovery techniques for athletes~4. Principles of stretching, strengthening and endurance training
Study: NCT06128135

Intervention type: OTHER
Intervention: Technology acceptance questionnaire for prostheses users.
Description: One questionnaire, which is for prosthesis users, where will be 15 questions to identify what kind of activities the person uses the prosthesis, how much is the use time and what is the main problem with the device.

Intervention type: OTHER
Intervention: Technology acceptance questionnaire for relatives of prostheses users.
Description: One questionnaire, where there will be between 8 questions to analyze which device characteristics, they think cause major discomfort during the use and could be improved.

Intervention type: OTHER
Intervention: Technology acceptance questionnaire for therapists
Description: One questionnaire, where there will be between 9 questions to analyze which device characteristics, they think cause major discomfort during the use and could be improved.
Study: NCT05759182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powered Exoskeleton Gait Training
Description: A trained medical professional will adjust the exoskeleton to fit each participant and tailor the program(sit to stand, stand to sit, standing balance and weight shift, walk in place, walk forward) according to their physical condition and specific needs. Based on each participant's walking ability, appropriate safety devices (such as crutches, canes, or a harness) will be used during the intervention.
Study: NCT05828667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incorporation of CT and/or c-MRI derived myocardial scar with 3D electroanatomical mapping (EAM).
Description: CT and/or c-MRI derived myocardial scar will be merged with 3D electroanatomical mapping (EAM) prior to the ablation to allow for readily localization and characterization of VT substrates and potential re-entry circuits to be ablated. This is done with the intent to limit the repeated number of inductions and prolonged point-by-point voltage mapping that often result in hemodynamic instability.
Study: NCT05565105

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: Hyper-fractioned TBI is administered by a linear accelerator at a dose rate of \< 15 cGy/minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa: 5 mg/kg/day IV over approximately 4 hours daily x 2 (Day -5 and Day -4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide: 60 mg/kg/day x 2 or Fludarabine 25 mg/m\^2 x 5 if cyclophosphamide is contraindicated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan: 0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan: 70 mg/m\^2/day x 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine: 25 mg/m\^2/day x 5
Study: NCT05489380

Intervention type: DEVICE
Group type: OTHER
Intervention: AccuMeasure
Description: intracolonoscopy measurement of polyps using a laser-based device

Intervention type: DEVICE
Group type: OTHER
Intervention: AccuMeasure
Description: intracolonoscopy measurement of polyps using a laser-based device
Study: NCT05025774

Intervention type: OTHER
Intervention: Physical activity
Description: Participant Reported Physical Activity and Outcomes (completed via REDCap or on paper)

Intervention type: OTHER
Intervention: Physical activity
Description: Participant Reported Physical Activity and Outcomes (completed via REDCap or on paper)
Study: NCT05917938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499
Description: NNC0194-0499 will be administered subcutaneously in a skinfold in the thigh in the form of a solution for injection.
Study: NCT05932316

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: spirometry
Description: participants will undertake spirometry testing before and after bronchodilators and placebo

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: spirometry
Description: participants will undertake spirometry testing before and after bronchodilators and placebo
Study: NCT05917938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499
Description: NNC0194-0499 will be administered subcutaneously in a skinfold in the thigh in the form of a solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499
Description: NNC0194-0499 will be administered subcutaneously in a skinfold in the thigh in the form of a solution for injection.
Study: NCT05932316

Intervention type: DRUG
Group type: OTHER
Intervention: Salbutamol
Description: Salbutamol inhalation to determine bronchodilator response
Study: NCT04928794

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Erector Spinae Plane Block
Description: Regional anesthesia with injected local anesthetic solution, placed in space underlying erector spinae muscles

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Paravertebral Block
Description: Regional anesthesia with injected local anesthetic solution, placed in space adjacent to vertebrae
Study: NCT06087198

Intervention type: DIAGNOSTIC_TEST
Intervention: T-TAS 01 HD Assay
Description: Disposable flow chamber microchip containing thrombogenic path to facilitate thrombus formation and occlusion

Intervention type: DIAGNOSTIC_TEST
Intervention: T-TAS 01 HD Assay
Description: Disposable flow chamber microchip containing thrombogenic path to facilitate thrombus formation and occlusion
Study: NCT05932316

Intervention type: DRUG
Group type: OTHER
Intervention: Salbutamol
Description: Salbutamol inhalation to determine bronchodilator response

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo inhalation prior to repeating spirometry

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo inhalation prior to repeating spirometry
Study: NCT05769153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-14034 SR implant lower dose
Description: AR-14034 SR administered as an intravitreal implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-14034 SR implant lower dose
Description: AR-14034 SR administered as an intravitreal implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Aflibercept administered as a 2 milligram (mg) intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Aflibercept administered as a 2 milligram (mg) intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept Injection
Description: Aflibercept administered as a 2 milligram (mg) intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Aflibercept administered as a 2 milligram (mg) intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Aflibercept administered as a 2 milligram (mg) intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham procedure
Description: Needleless syringe used to simulate an intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham procedure
Description: Needleless syringe used to simulate an intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham procedure
Description: Needleless syringe used to simulate an intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-14034 SR implant higher dose
Description: AR-14034 SR administered as an intravitreal implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-14034 SR implant higher dose
Description: AR-14034 SR administered as an intravitreal implant
Study: NCT05437146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: puppet
Description: pain and fear during blood collection
Study: NCT05640908

Intervention type: DEVICE
Intervention: iFuse Bedrock Granite Implant System
Description: Surgical procedure of the spine with pelvic fixation/fusion using iFuse Bedrock Granite
Study: NCT04943913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
Study: NCT06271941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid Argon Plasma Coagulation (h-APC)
Description: The hybrid argon plasma coagulation (h-APC) combines an ablation technique (APC) with the option for submucosal saline injection using a high-pressure water jet. The technique allows for the lifting of dysplastic epithelium, creating a cushion under the mucosa to facilitate the ablation of larger areas more thoroughly and with higher energy settings, while posing a low risk for side effects or complications.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Snare tip soft coagulation (STSC)
Description: The Snare tip soft coagulation (STSC) involves using a snare to remove polyps, while simultaneously applying soft coagulation to the surrounding tissue using a specialized tip on the snare.
Study: NCT04476654

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: YouTube Video Arm
Description: Participants (n=25) will watch a 20 minute YouTube video that will describe the genetic counseling and testing process and risk/benefit information in a culturally relevant format. Participants will complete pre and post assessments. After the session, participants interested in pursuing genetic counseling and testing services will be referred to a patient navigator who will navigate participants to identified no cost or low cost services.
Study: NCT06087991

Intervention type: BEHAVIORAL
Intervention: Implementation of the BINDeR-Tx service model
Description: ED-initiated buprenorphine, discharge with naloxone, and warm-hand off referral for continued treatment for individuals with OUD. This is considered standard treatment at the University of Utah ED. In order to extend these services to rural hospitals this study will be assisting Castleview Hospital to establish a similar program.

Intervention type: BEHAVIORAL
Intervention: Implementation of the BINDeR-Tx service model
Description: ED-initiated buprenorphine, discharge with naloxone, and warm-hand off referral for continued treatment for individuals with OUD. This is considered standard treatment at the University of Utah ED. In order to extend these services to rural hospitals this study will be assisting Castleview Hospital to establish a similar program.
Study: NCT04055129

Intervention type: OTHER
Intervention: No interventions
Description: Observational. Data will be gathered and analyzed on ligament laxity, EMG, kinetics and kinematics during a landing and jumping activity

Intervention type: OTHER
Intervention: No interventions
Description: Observational. Data will be gathered and analyzed on ligament laxity, EMG, kinetics and kinematics during a landing and jumping activity
Study: NCT05814562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Intervention
Description: The study utilizes a tailored telemetric intervention to improve adherence to medications. The telemetric intervention (administered via telephone, or interactive internet chat applications such as Zoom ©, FaceTime ® or Skype ®) will enable experienced therapists to address nonadherence from a remote location, using a structured, tailored approach that accommodates specific patient needs.
Study: NCT06424301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeting NUDT21 siRNA drugs
Description: It is performed for intravitreal chemotherapy.
Study: NCT05497908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block via lateral approach
Description: TAP block via lateral approach

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block via posterior approach
Description: TAP block via posterior approach
Study: NCT06331208

Intervention type: DIAGNOSTIC_TEST
Intervention: non-contrast chest CT
Description: patients who undergo clinically indicated evaluation of pulmonary circulation (right heart catheterisation - RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: non-contrast chest CT
Description: patients who undergo clinically indicated evaluation of pulmonary circulation (right heart catheterisation - RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
Study: NCT06400329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: PNE focuses more on the neurophysiology of pain and approaches it from the perspective that knee OA pain is manageable, using neutral to positive language and emphasizes the importance of physical function and staying active

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pain Education
Description: In Standard Pain Education, the emphasis is on the structural pathology of knee OA and the outdated but common understanding of the disease process as a degenerative one, potentially conveying negative and threatening language
Study: NCT06331208

Intervention type: DIAGNOSTIC_TEST
Intervention: spirometry with diffusing lung capacity for carbon monoxide (DLCO) analysis
Description: patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: spirometry with diffusing lung capacity for carbon monoxide (DLCO) analysis
Description: patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
Study: NCT05116761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
Description: Intravenous administration of Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo Saline
Study: NCT05813275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD109
Description: Oral administration at bedtime
Study: NCT06331208

Intervention type: DIAGNOSTIC_TEST
Intervention: Omics analysis of blood plasma obtained from pulmonary artery or peripheral blood
Description: patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.
Study: NCT05813275

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration at bedtime
Study: NCT06331208

Intervention type: DIAGNOSTIC_TEST
Intervention: Omics analysis of blood plasma obtained from pulmonary artery or peripheral blood
Description: patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: supine bike exercise during right heart catheterisation
Description: subgroup of HF subjects who undergo right heart catheterisation will perform short supine bike exercise during RHC

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ventilation/perfusion SPECT
Description: subgroup of HF subjects will undergo ventilation/perfusion SPECT
Study: NCT05487170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNK05047
Description: RNK05047 is a chaperone-mediated protein degrader administered as IV infusion once weekly for 3 consecutive weeks in a 4-week cycle (no treatment in the fourth week).
Study: NCT05166967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individual Antithymocyte globulin
Description: Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 13mg/kg). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antithymocyte globulin
Description: A 10mg/kg total dose of antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (from day -5 to day -2). Prophylaxis against graft versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate.
Study: NCT05464628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC42
Description: Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
Study: NCT05691075

Intervention type: PROCEDURE
Intervention: Arthrodesis of the metatarsophalangeal joint
Description: Isolated surgery of the first ray of hallux valgus, hallux varus or hallux rigidus by percutaneous or conventional approach

Intervention type: PROCEDURE
Intervention: Arthrodesis of the metatarsophalangeal joint
Description: Isolated surgery of the first ray of hallux valgus, hallux varus or hallux rigidus by percutaneous or conventional approach
Study: NCT05049902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Use according to the drug combination options selected by each center.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Use according to the drug combination options selected by each center.
Study: NCT05505981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate PT
Description: Patients will start PT immediately

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rest until pain resolves
Description: Patients will wait to start PT until their pain resolves